{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ASV+therapy", "query": { "intervention": "ASV therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ASV+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T11:21:26.399Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02098616", "title": "Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "DCV/ASV/BMS-791325", "type": "DRUG" }, { "name": "DCV/ASV/BMS-791325 + RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Timothy Morgan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-07", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-04-19", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098616" }, { "nct_id": "NCT04133350", "title": "Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy (PEP ASV)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sleep Disorder; Breathing-Related", "Heart Failure" ], "interventions": [ { "name": "Active Patient Engagement", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-10-16", "completion_date": "2021-02-01", "has_results": false, "last_update_posted_date": "2021-05-27", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Falls Church, Virginia", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04133350" }, { "nct_id": "NCT01888900", "title": "New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis", "Chronic Hepatitis C", "Hepatitis C", "Hepatitis C, Chronic" ], "interventions": [ { "name": "DUAL", "type": "DRUG" }, { "name": "QUAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2013-05", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888900" }, { "nct_id": "NCT01428063", "title": "Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Asunaprevir", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2011-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-05-27", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 20, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01428063" }, { "nct_id": "NCT01973049", "title": "UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Asunaprevir", "type": "DRUG" }, { "name": "BMS-791325", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo matching Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-12", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 26, "location_summary": "La Jolla, California • San Diego, California • San Francisco, California + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01973049" }, { "nct_id": "NCT02095860", "title": "Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "DCV 3DAA FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 24, "start_date": "2014-04", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-10-10", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02095860" }, { "nct_id": "NCT01455090", "title": "Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "BMS-650032", "type": "DRUG" }, { "name": "BMS-790052", "type": "DRUG" }, { "name": "BMS-791325", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2011-11-30", "completion_date": "2015-07-31", "has_results": false, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Coronado, California • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01455090" }, { "nct_id": "NCT01030432", "title": "Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-650032", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 285, "start_date": "2010-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030432" }, { "nct_id": "NCT03195660", "title": "Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Failure With Normal Ejection Fraction", "Sleep Apnea" ], "interventions": [ { "name": "ASV Therapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "ResMed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2017-06-26", "completion_date": "2017-11-15", "has_results": true, "last_update_posted_date": "2021-05-14", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 3, "location_summary": "San Diego, California • Philadelphia, Pennsylvania • Falls Church, Virginia", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03195660" }, { "nct_id": "NCT01581203", "title": "Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Asunaprevir (ASV)", "type": "DRUG" }, { "name": "Daclatasvir (DCV)", "type": "DRUG" }, { "name": "Pegylated-interferon alfa 2a (PegIFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 748, "start_date": "2012-05", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-10T11:21:26.399Z", "location_count": 18, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01581203" } ] }